---
document_datetime: 2025-12-02 05:12:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/esmya.html
document_name: esmya.html
version: success
processing_time: 0.1307366
conversion_datetime: 2025-12-27 17:06:47.382485
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Esmya

[RSS](/en/individual-human-medicine.xml/66291)

##### Withdrawn

This medicine's authorisation has been withdrawn

ulipristal Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Esmya](#news-on)
- [More information on Esmya](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 July 2024, the European Commission withdrew the marketing authorisation for Esmya (ulipristal acetate) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Gedeon Richter Plc., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Esmya was granted marketing authorisation in the EU on 23 February 2012 for the treatment of uterine fibroids. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016.

The European Public Assessment Report (EPAR) for Esmya will be updated to indicate that the marketing authorisation is no longer valid.

Esmya : EPAR - Medicine overview

Adopted

Reference Number: EMA/141458/2012

English (EN) (210.05 KB - PDF)

**First published:** 15/03/2012

**Last updated:** 03/02/2021

[View](/en/documents/overview/esmya-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-193)

български (BG) (275.47 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/bg/documents/overview/esmya-epar-medicine-overview_bg.pdf)

español (ES) (211.43 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/es/documents/overview/esmya-epar-medicine-overview_es.pdf)

čeština (CS) (248.67 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/cs/documents/overview/esmya-epar-medicine-overview_cs.pdf)

dansk (DA) (206.07 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/da/documents/overview/esmya-epar-medicine-overview_da.pdf)

Deutsch (DE) (216.09 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/de/documents/overview/esmya-epar-medicine-overview_de.pdf)

eesti keel (ET) (195.31 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/et/documents/overview/esmya-epar-medicine-overview_et.pdf)

ελληνικά (EL) (278.79 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/el/documents/overview/esmya-epar-medicine-overview_el.pdf)

français (FR) (212.74 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/fr/documents/overview/esmya-epar-medicine-overview_fr.pdf)

hrvatski (HR) (243.81 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/hr/documents/overview/esmya-epar-medicine-overview_hr.pdf)

italiano (IT) (203.73 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/it/documents/overview/esmya-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (261.58 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/lv/documents/overview/esmya-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (246.29 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/lt/documents/overview/esmya-epar-medicine-overview_lt.pdf)

magyar (HU) (235.86 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/hu/documents/overview/esmya-epar-medicine-overview_hu.pdf)

Malti (MT) (265.33 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/mt/documents/overview/esmya-epar-medicine-overview_mt.pdf)

Nederlands (NL) (211.03 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/nl/documents/overview/esmya-epar-medicine-overview_nl.pdf)

polski (PL) (249.35 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/pl/documents/overview/esmya-epar-medicine-overview_pl.pdf)

português (PT) (209.79 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/pt/documents/overview/esmya-epar-medicine-overview_pt.pdf)

română (RO) (250.59 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/ro/documents/overview/esmya-epar-medicine-overview_ro.pdf)

slovenčina (SK) (244.89 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/sk/documents/overview/esmya-epar-medicine-overview_sk.pdf)

slovenščina (SL) (245.13 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/sl/documents/overview/esmya-epar-medicine-overview_sl.pdf)

Suomi (FI) (201.57 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/fi/documents/overview/esmya-epar-medicine-overview_fi.pdf)

svenska (SV) (207.95 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/sv/documents/overview/esmya-epar-medicine-overview_sv.pdf)

Esmya : EPAR - Risk-management-plan summary

English (EN) (349.58 KB - PDF)

**First published:** 19/11/2018

**Last updated:** 03/02/2021

[View](/en/documents/rmp-summary/esmya-epar-risk-management-plan-summary_en.pdf)

## Product information

Esmya : EPAR - Product Information

English (EN) (1.15 MB - PDF)

**First published:** 15/03/2012

**Last updated:** 03/02/2021

[View](/en/documents/product-information/esmya-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-41)

български (BG) (1.56 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/bg/documents/product-information/esmya-epar-product-information_bg.pdf)

español (ES) (1.2 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/es/documents/product-information/esmya-epar-product-information_es.pdf)

čeština (CS) (1.28 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/cs/documents/product-information/esmya-epar-product-information_cs.pdf)

dansk (DA) (1.13 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/da/documents/product-information/esmya-epar-product-information_da.pdf)

Deutsch (DE) (1.27 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/de/documents/product-information/esmya-epar-product-information_de.pdf)

eesti keel (ET) (919.58 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/et/documents/product-information/esmya-epar-product-information_et.pdf)

ελληνικά (EL) (1.77 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/el/documents/product-information/esmya-epar-product-information_el.pdf)

français (FR) (1.24 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/fr/documents/product-information/esmya-epar-product-information_fr.pdf)

hrvatski (HR) (1.37 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/hr/documents/product-information/esmya-epar-product-information_hr.pdf)

íslenska (IS) (1.09 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/is/documents/product-information/esmya-epar-product-information_is.pdf)

italiano (IT) (1.17 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/it/documents/product-information/esmya-epar-product-information_it.pdf)

latviešu valoda (LV) (1.37 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/lv/documents/product-information/esmya-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.36 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/lt/documents/product-information/esmya-epar-product-information_lt.pdf)

magyar (HU) (1.31 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/hu/documents/product-information/esmya-epar-product-information_hu.pdf)

Malti (MT) (1.41 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/mt/documents/product-information/esmya-epar-product-information_mt.pdf)

Nederlands (NL) (1.21 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/nl/documents/product-information/esmya-epar-product-information_nl.pdf)

norsk (NO) (1.14 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/no/documents/product-information/esmya-epar-product-information_no.pdf)

polski (PL) (1.4 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/pl/documents/product-information/esmya-epar-product-information_pl.pdf)

português (PT) (1.18 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/pt/documents/product-information/esmya-epar-product-information_pt.pdf)

română (RO) (1.41 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/ro/documents/product-information/esmya-epar-product-information_ro.pdf)

slovenčina (SK) (1.3 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/sk/documents/product-information/esmya-epar-product-information_sk.pdf)

slovenščina (SL) (1.27 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/sl/documents/product-information/esmya-epar-product-information_sl.pdf)

Suomi (FI) (1.16 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/fi/documents/product-information/esmya-epar-product-information_fi.pdf)

svenska (SV) (1.08 MB - PDF)

**First published:**

15/03/2012

**Last updated:**

03/02/2021

[View](/sv/documents/product-information/esmya-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** A31/0049 11/01/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Esmya : EPAR - All Authorised presentations

English (EN) (48.74 KB - PDF)

**First published:** 15/03/2012

**Last updated:** 27/05/2014

[View](/en/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-370)

български (BG) (95.68 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/bg/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_bg.pdf)

español (ES) (61.96 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/es/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_es.pdf)

čeština (CS) (66.59 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/cs/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (58.48 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/da/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (54.62 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/de/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (56.81 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/et/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (91.42 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/el/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_el.pdf)

français (FR) (56.72 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/fr/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.41 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/hr/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (58.05 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/is/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.47 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/it/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (87.06 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/lv/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (89.44 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/lt/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (91.81 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/hu/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (86.31 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/mt/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (58.81 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/nl/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (58.12 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/no/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_no.pdf)

polski (PL) (67.93 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/pl/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_pl.pdf)

português (PT) (57.43 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/pt/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_pt.pdf)

română (RO) (86.2 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/ro/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (69.46 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/sk/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (72.13 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/sl/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.37 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/fi/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (58.85 KB - PDF)

**First published:**

15/03/2012

**Last updated:**

27/05/2014

[View](/sv/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Esmya Active substance ulipristal acetate International non-proprietary name (INN) or common name ulipristal Therapeutic area (MeSH) Leiomyoma Anatomical therapeutic chemical (ATC) code G03XB02

### Pharmacotherapeutic group

Sex hormones and modulators of the genital system

### Therapeutic indication

Ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

## Authorisation details

EMA product number EMEA/H/C/002041 Marketing authorisation holder

Gedeon Richter Ltd

Gedeon Richter Ltd

Opinion adopted 15/12/2011 Marketing authorisation issued 22/02/2012 Withdrawal of marketing authorisation 18/07/2024 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Esmya : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (794.83 KB - PDF)

**First published:** 06/09/2012

**Last updated:** 03/02/2021

[View](/en/documents/procedural-steps-after/esmya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Esmya : EPAR - Scientific conclusions - Annex IV

English (EN) (440.77 KB - PDF)

**First published:** 03/02/2021

[View](/en/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_en.pdf)

[Other languages (24)](#file-language-dropdown-433)

български (BG) (792.72 KB - PDF)

**First published:**

03/02/2021

[View](/bg/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_bg.pdf)

español (ES) (485.06 KB - PDF)

**First published:**

03/02/2021

[View](/es/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_es.pdf)

čeština (CS) (642 KB - PDF)

**First published:**

03/02/2021

[View](/cs/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_cs.pdf)

dansk (DA) (475.85 KB - PDF)

**First published:**

03/02/2021

[View](/da/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_da.pdf)

Deutsch (DE) (539.09 KB - PDF)

**First published:**

03/02/2021

[View](/de/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_de.pdf)

eesti keel (ET) (633.74 KB - PDF)

**First published:**

03/02/2021

[View](/et/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_et.pdf)

ελληνικά (EL) (867.35 KB - PDF)

**First published:**

03/02/2021

[View](/el/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_el.pdf)

français (FR) (506.15 KB - PDF)

**First published:**

03/02/2021

[View](/fr/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_fr.pdf)

hrvatski (HR) (662.85 KB - PDF)

**First published:**

03/02/2021

[View](/hr/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_hr.pdf)

íslenska (IS) (461.5 KB - PDF)

**First published:**

03/02/2021

[View](/is/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_is.pdf)

italiano (IT) (519.62 KB - PDF)

**First published:**

03/02/2021

[View](/it/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_it.pdf)

latviešu valoda (LV) (711.89 KB - PDF)

**First published:**

03/02/2021

[View](/lv/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_lv.pdf)

lietuvių kalba (LT) (749.02 KB - PDF)

**First published:**

03/02/2021

[View](/lt/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_lt.pdf)

magyar (HU) (624.15 KB - PDF)

**First published:**

03/02/2021

[View](/hu/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_hu.pdf)

Malti (MT) (759.86 KB - PDF)

**First published:**

03/02/2021

[View](/mt/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_mt.pdf)

Nederlands (NL) (503.62 KB - PDF)

**First published:**

03/02/2021

[View](/nl/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_nl.pdf)

norsk (NO) (458.17 KB - PDF)

**First published:**

03/02/2021

[View](/no/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_no.pdf)

polski (PL) (724.19 KB - PDF)

**First published:**

03/02/2021

[View](/pl/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_pl.pdf)

português (PT) (472.57 KB - PDF)

**First published:**

03/02/2021

[View](/pt/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_pt.pdf)

română (RO) (742.93 KB - PDF)

**First published:**

03/02/2021

[View](/ro/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_ro.pdf)

slovenčina (SK) (629.32 KB - PDF)

**First published:**

03/02/2021

[View](/sk/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_sk.pdf)

slovenščina (SL) (636.66 KB - PDF)

**First published:**

03/02/2021

[View](/sl/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_sl.pdf)

Suomi (FI) (472.99 KB - PDF)

**First published:**

03/02/2021

[View](/fi/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_fi.pdf)

svenska (SV) (464.54 KB - PDF)

**First published:**

03/02/2021

[View](/sv/documents/scientific-conclusion/esmya-epar-scientific-conclusions-annex-iv_sv.pdf)

Ulipristal Acetate Gedeon Richter / Esmya-H-A-31-1496-C-2041-0049: EPAR - CHMP scientific conclusions and PRAC Assessment report - Article 31

Adopted

Reference Number: EMA/524073/2020

English (EN) (1.4 MB - PDF)

**First published:** 03/02/2021

**Last updated:** 02/07/2021

[View](/en/documents/variation-report/ulipristal-acetate-gedeon-richter-esmya-h-31-1496-c-2041-0049-epar-chmp-scientific-conclusions-and-prac-assessment-report-article-31_en.pdf)

Esmya-H-C-2041-A20-0043 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/442745/2018

English (EN) (1.35 MB - PDF)

**First published:** 08/08/2018

**Last updated:** 08/08/2018

[View](/en/documents/variation-report/esmya-h-c-2041-a20-0043-epar-assessment-report-article-20_en.pdf)

Esmya-H-C-2041-A20-0043 : EPAR - Divergent position of CHMP - Article 20

English (EN) (49.4 KB - PDF)

**First published:** 08/08/2018

**Last updated:** 08/08/2018

[View](/en/documents/scientific-conclusion/esmya-h-c-2041-a20-0043-epar-divergent-position-chmp-article-20_en.pdf)

Esmya-H-C-PSUSA-00009325-201702 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/11208/2018

English (EN) (118.9 KB - PDF)

**First published:** 10/01/2018

**Last updated:** 10/01/2018

[View](/en/documents/scientific-conclusion/esmya-h-c-psusa-00009325-201702-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Esmya-H-C-2041-II-0028 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/84021/2015

English (EN) (7.35 MB - PDF)

**First published:** 07/07/2015

**Last updated:** 07/07/2015

[View](/en/documents/variation-report/esmya-h-c-2041-ii-0028-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Esmya

Adopted

Reference Number: EMA/CHMP/245897/2015

English (EN) (107.72 KB - PDF)

**First published:** 24/04/2015

**Last updated:** 24/04/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-esmya_en.pdf)

## Initial marketing authorisation documents

Esmya : EPAR - Public assessment report

Adopted

Reference Number: EMA/141637/2012

English (EN) (4.98 MB - PDF)

**First published:** 15/03/2012

**Last updated:** 03/08/2018

[View](/en/documents/assessment-report/esmya-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Esmya

Adopted

Reference Number: EMA/679632/2011

English (EN) (137.48 KB - PDF)

**First published:** 16/12/2011

**Last updated:** 16/12/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-esmya_en.pdf)

#### News on Esmya

[Ulipristal acetate for uterine fibroids: EMA recommends restricting use](/en/news/ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use) 13/11/2020

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31  August - 3 September 2020](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-31-august-3-september-2020) 04/09/2020

[PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids](/en/news/prac-recommends-revoking-marketing-authorisation-ulipristal-acetate-uterine-fibroids) 04/09/2020

[Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk](/en/news/suspension-ulipristal-acetate-uterine-fibroids-during-ongoing-ema-review-liver-injury-risk) 13/03/2020

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 March 2020](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-march-2020) 13/03/2020

[Esmya: new measures to minimise risk of rare but serious liver injury](/en/news/esmya-new-measures-minimise-risk-rare-serious-liver-injury-0) 08/08/2018

[Esmya: new measures to minimise risk of rare but serious liver injury](/en/news/esmya-new-measures-minimise-risk-rare-serious-liver-injury) 01/06/2018

[PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids](/en/news/prac-recommends-new-measures-minimise-risk-rare-serious-liver-injury-esmya-fibroids) 18/05/2018

[Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing](/en/news/women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing) 09/02/2018

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2017](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-november-2017) 01/12/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

#### More information on Esmya

- [Esmya - referral](/en/medicines/human/referrals/esmya)
- [Ulipristal acetate 5mg medicinal products - referral](/en/medicines/human/referrals/ulipristal-acetate-5mg-medicinal-products)
- [Esmya / Ulipristal Acetate Gedeon Richter - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/esmya-ulipristal-acetate-gedeon-richter)
- [Esmya ® Prescription Patterns in Europe: A Retrospective Drug Utilization Chart Review Study - post-authorisation study](https://catalogues.ema.europa.eu/study/8534)
- [A prospective, multi-national, multicentre, non-interventional study to evaluate the long term safety of Esmya, in particular the endometrial safety, and the current prescription and management patterns of Esmya in a long term treatment setting - post-authorisation study](https://catalogues.ema.europa.eu/study/28785)

**This page was last updated on** 20/08/2025

## Share this page

[Back to top](#main-content)